Literature DB >> 12395148

Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.

Han-Mou Tsai1.   

Abstract

Von Willebrand factor (vWF), a glycoprotein critical for supporting platelet adhesion and aggregation at sites of vessel injury, exists in the plasma as a series of multimers. Recent studies have shown that a metalloprotease cleaves endothelial vWF to a series of multimers. A deficiency of the protease activity due to autoimmune IgG inhibitors or genetic mutations is associated with thrombotic thrombocytopenic purpura (TTP). Positional cloning based on kindreds with a genetic deficiency of the protease and amino acid sequencing of the purified protein have identified the protease as a novel member of the ADAMTS (a disintegrin and metalloprotease with thrombospondin type 1 repeat) zinc metalloprotease family located on the long arm of chromosome 9. Mutations of the gene are detected in patients with the congenital form of TTP. These findings support the view that vWF proteolysis is critical in regulating vWF-platelet interaction and set the stage for improving the diagnosis and treatment of thrombotic thrombocytopenic purpura.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12395148     DOI: 10.1007/s00109-002-0369-8

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  10 in total

Review 1.  ADAMTS13 and microvascular thrombosis.

Authors:  Han-Mou Tsai
Journal:  Expert Rev Cardiovasc Ther       Date:  2006-11

2.  Why Do We Need ADAMTS13?

Authors:  Han-Mou Tsai
Journal:  Nihon Kessen Shiketsu Gakkai shi       Date:  2005

3.  Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions.

Authors:  Zhenyin Tao; Yuandong Peng; Leticia Nolasco; Santiago Cal; Carlos Lopez-Otin; Renhao Li; Joel L Moake; José A López; Jing-Fei Dong
Journal:  Blood       Date:  2005-09-01       Impact factor: 22.113

4.  Formation and Resolution of Pial Microvascular Thrombosis in a Mouse Model of Thrombotic Thrombocytopenic Purpura.

Authors:  Reheman Adili; Michael Holinstat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-07-25       Impact factor: 8.311

Review 5.  Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Kidney Int Suppl       Date:  2009-02       Impact factor: 10.545

6.  The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis.

Authors:  Anil K Chauhan; Meghan T Walsh; Guojing Zhu; David Ginsburg; Denisa D Wagner; David G Motto
Journal:  Blood       Date:  2007-12-14       Impact factor: 22.113

7.  [Thrombotic thrombocytopenic purpura. Reduced activity of von Willebrand factor cleaving protease].

Authors:  A Kunze; C Terborg; J Gerth; G Heide; O W Witte
Journal:  Nervenarzt       Date:  2004-08       Impact factor: 1.214

8.  Decreased plasma ADAMTS-13 activity as a predictor of postoperative bleeding in cyanotic congenital heart disease.

Authors:  Rosangela P S Soares; Sérgio P Bydlowski; Marcelo B Jatene; Janete Ferreira Hironaka; Antonio Augusto Lopes
Journal:  Clinics (Sao Paulo)       Date:  2013-04       Impact factor: 2.365

Review 9.  Proteolytic processing of von Willebrand factor by adamts13 and leukocyte proteases.

Authors:  Stefano Lancellotti; Maria Basso; Raimondo De Cristofaro
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-09-02       Impact factor: 2.576

10.  Plasmatic ADAMTS-13 metalloprotease and von Willebrand factor in children with cyanotic congenital heart disease.

Authors:  R P S Soares; S P Bydlowski; N M Nascimento; A M Thomaz; E N M Bastos; A A Lopes
Journal:  Braz J Med Biol Res       Date:  2013-04-05       Impact factor: 2.590

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.